Clinical Trials Monitor/
RecruitingNANCT06155643

EKO SENSORA: Detecting Clinically Significant Murmurs

Sponsor: Corewell Health South

Trial Details

ConditionHeart Murmurs
InterventionEko Sensora
PhaseNA
StatusRecruiting
Participants300
Est. Completion26 July 2027
Last Updated20 July 2026

Primary Outcome

Number of new clinically significant heart murmurs detected

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Chief complaint of chest pain, shortness of breath, difficulty breathing, or syncope/near-syncope. * Patients with chief complaint of Weakness would be eligible if over the age of 50 and have a history of at least two of hypertension, BMI\>/= 30, diabetes, hyperlipidemia, atrial fibrillation, heart attack, stroke/Transient ischemic attack, prior cardiac surgery or angiography Exclusion Criteria: * Contact isolation patients * Pediatric patients under the age of 18

Trial Sites

Countries

United States
View Registry Entry

Related Analysis

AI-Powered Digital Stethoscope Trial Opens in Emergency Department: Can Eko Sensora Catch Clinically Significant Murmurs That Clinicians Miss?

A new prospective study at Corewell Health South is evaluating whether the Eko Sensora AI-powered digital stethoscope can improve detection of clinically significant heart murmurs in emergency department patients presenting with chest pain, dyspnoea, or syncope. With valvular heart disease frequently missed in high-acuity settings, this trial could reshape how cardiac auscultation is integrated into emergency workflows. Enrolment is open for 300 adult participants, with results expected by mid-2027.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service